Home > D. Systemic pathology > Toxics and drugs > aflibercept
aflibercept
Monday 11 June 2007
VEGF-Trap, Zaltrap
| Wikipedia |
Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF).
Aflibercept is designed to bind to VEGF-A, VEGF-B, and placental growth factor (PIGF).
Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals.
Aflibercept is a fusion protein approved in the United States for the treatment of wet macular degeneration. It is under development for the treatment of cancer.
Clinical trials
In March 2011, Regeneron reported that aflibercept failed its primary endpoint of overall survival in the Vital phase III trial for second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), although it improved the secondary endpoint of progression-free survival
In April 2011, Regeneron reported that aflibercept improved its primary endpoint of overall survival in the Velour phase III clinical trial for second-line treatment for metastatic colorectal cancer (mCRC).
Aflibercept is also in a phase III trial for hormone-refractory metastatic prostate cancer.
